Validation
Gene Symbol |
Curated Descriptions | Cell Lines | Isolations | Validations | Control-case | Tumor Stage & Subtype | Clinical Use | PMID |
|---|---|---|---|---|---|---|---|---|
| hsa-miR-10b | Hsa-miR-10b has significantly up-regulated and has been extensively implicated in cancer progression | MCF7,MDA-MB-2314T1 | ultracentrifugation | transmission electron microscopy | 11 breast cancer samples (case) 8 healthy samples (control) | triple negative metastatic breast carcinoma | 25446899 | |
| hsa-miR-10b | Hsa-miR-10b secretes protein levels that inhibit its target genes such as HOXD10 and KLF4 and induces invasion of breast cancer cells | MDA-MB-231 | centrifugation | scanning electron and confocal microscopy | metastasis | 25428807 | ||
| hsa-miR-122 | Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer | ultracentrifugation, Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) | electron microscopy,nanoparticle tracking analysis,and western blot | 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) | ER+/-,PR+/-,HER2+/- stages II, III breast cancer | 27608715 | ||
| hsa-miR-122 | Hsa-miR-122 suppresses glucose uptake by downregulating the glycolytic enzyme pyruvate kinase (PKM)to promote metastasis | MDA-MB-231 | centrifugation | transmission electron microscope | metastasis | 25621950 | ||
| hsa-miR-124-3p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-miR-1246 | Hsa-miR-1246 promotes cell proliferation,invasion and drug resistance by targeting CCNG2 in breast cancer | MDA-MB-231 | ultracentrifugation | scanning electron and confocal microscopy | metastasis | 29216623 | ||
| hsa-miR-1246 | Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer | ultracentrifugation, Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) | electron microscopy,nanoparticle tracking analysis,and western blot | 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) | ER+/-,PR+/-,HER2+/- stages II, III breast cancer | 27608715 | ||
| hsa-miR-128 | Hsa-miR-128 negatively regulates the level of Bax in MCF7recipient cells and inhibits cell proliferation | MCF7 | centrifugation | transmission electron microscopy,Nanoparticle Tracking Analysis | 27322220 | |||
| hsa-miR-130a | Comparing the miRNAs in MDA-Exo to MCF-Exo showed a higher expression of tumorigenic mir-130a in MDA-Exo. it has been shown that mir-130a contribute to tumorigenesis of colon cancer by regulating TGB-β/Smad signaling | MCF7,MDA-MB231 | ultracentrifugation | electron microscopy | 24468161 | |||
| hsa-miR-130a-3p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 |